PT2266544T - Método para introdução de substâncias terapêuticas em células - Google Patents

Método para introdução de substâncias terapêuticas em células

Info

Publication number
PT2266544T
PT2266544T PT100123942T PT10012394T PT2266544T PT 2266544 T PT2266544 T PT 2266544T PT 100123942 T PT100123942 T PT 100123942T PT 10012394 T PT10012394 T PT 10012394T PT 2266544 T PT2266544 T PT 2266544T
Authority
PT
Portugal
Prior art keywords
cells
therapeutic substances
introducing therapeutic
introducing
substances
Prior art date
Application number
PT100123942T
Other languages
English (en)
Inventor
Jordan Andreas
Waldöfner Norbert
Scholz Regina
Original Assignee
Magforce Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Magforce Ag filed Critical Magforce Ag
Publication of PT2266544T publication Critical patent/PT2266544T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/136—Amines having aromatic rings, e.g. ketamine, nortriptyline having the amino group directly attached to the aromatic ring, e.g. benzeneamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/40—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals
    • A61N1/403—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia
    • A61N1/406—Applying electric fields by inductive or capacitive coupling ; Applying radio-frequency signals for thermotherapy, e.g. hyperthermia using implantable thermoseeds or injected particles for localized hyperthermia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/70—Nanostructure
    • Y10S977/773—Nanoparticle, i.e. structure having three dimensions of 100 nm or less

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT100123942T 2005-08-19 2006-08-21 Método para introdução de substâncias terapêuticas em células PT2266544T (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102005039579.1A DE102005039579B4 (de) 2005-08-19 2005-08-19 Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
US71140705P 2005-08-26 2005-08-26

Publications (1)

Publication Number Publication Date
PT2266544T true PT2266544T (pt) 2017-08-16

Family

ID=39676367

Family Applications (1)

Application Number Title Priority Date Filing Date
PT100123942T PT2266544T (pt) 2005-08-19 2006-08-21 Método para introdução de substâncias terapêuticas em células

Country Status (16)

Country Link
US (3) US20080187595A1 (pt)
EP (2) EP2266544B1 (pt)
JP (1) JP5512968B2 (pt)
KR (2) KR20080034925A (pt)
CN (2) CN101299998A (pt)
AU (1) AU2006281783B2 (pt)
BR (1) BRPI0614835A2 (pt)
CA (1) CA2619278C (pt)
DE (1) DE102005039579B4 (pt)
DK (1) DK2266544T3 (pt)
ES (1) ES2635493T3 (pt)
IL (1) IL189079A (pt)
PL (1) PL2266544T3 (pt)
PT (1) PT2266544T (pt)
RU (1) RU2480201C2 (pt)
WO (1) WO2007019845A2 (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen
US8093038B2 (en) 2007-09-17 2012-01-10 Illinois Institute Of Technology Apparatus and method for encapsulating pancreatic cells
DE102008003615A1 (de) * 2008-01-09 2009-07-16 Magforce Nanotechnologies Ag Magnetische Transducer
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
US8236284B1 (en) 2008-04-02 2012-08-07 University Of Central Florida Research Foundation, Inc. Multimodal, multifunctional polymer coated nanoparticles
US20110212142A1 (en) * 2008-11-17 2011-09-01 Laila Pharmaceuticals Pvt.Ltd. Curcuminoids and its metabolites for the application in ocular diseases
JP5739816B2 (ja) 2008-12-19 2015-06-24 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉインヒビターおよび使用法
US20110311452A1 (en) * 2008-12-23 2011-12-22 Board Of Regents Of The University Of Texas System Inflammation targeting particles
PL222496B1 (pl) 2009-04-10 2016-08-31 Inst Biochemii I Biofizyki Pan Wektorowa cząsteczka wirusopodobna, sposób jej wytwarzania oraz kompozycja farmaceutyczna zawierająca wektorową cząsteczkę wirusopodobną
CN101885905B (zh) * 2009-05-12 2013-08-21 无锡纳奥新材料科技有限公司 聚合物/无机纳米粒子复合纳米颗粒及其制备和用途
CN101991597B (zh) * 2009-08-29 2012-07-04 鲁南制药集团股份有限公司 一种口服药物组合物在制备预防或治疗肾脏疾病药物中的用途
CN101991596B (zh) * 2009-08-29 2012-02-01 鲁南制药集团股份有限公司 一种口服药物组合物在制备预防或治疗冠心病的药物中的用途
WO2011053901A2 (en) 2009-10-30 2011-05-05 Northwestern University Magnetic nanostructures as theranostic agents
EP2528601A1 (en) 2010-01-26 2012-12-05 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions and methods for prevention and treatment of pulmonary hypertension
NZ603028A (en) 2010-03-19 2014-11-28 Baxter Healthcare Sa Tfpi inhibitors and methods of use
KR101668029B1 (ko) 2010-04-16 2016-10-20 코웨이 주식회사 라파콜을 유효성분으로 포함하는 주름개선용 화장료 조성물
CA2798180A1 (en) 2010-05-03 2011-11-10 Teikoku Pharma Usa, Inc. Non-aqueous taxane pro-emulsion formulations and methods of making and using the same
WO2011146819A2 (en) * 2010-05-20 2011-11-24 Dmd Therapies, Llc METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES
WO2011150212A2 (en) * 2010-05-26 2011-12-01 The General Hospital Corporation Magnetic nanoparticles
EP2450058A1 (en) * 2010-08-23 2012-05-09 Matera Lda Antimicrobial nanoparticle conjugates
WO2012081038A2 (en) * 2010-12-17 2012-06-21 Godavari Biorefineries Limited Anticancer compounds and targeting cancer with the same
JP2014515007A (ja) 2011-02-25 2014-06-26 サウス ダコタ ステート ユニバーシティー 局所送達のためのタンパク質ナノ担体
ES2807209T3 (es) * 2011-08-10 2021-02-22 Magforce Ag Método para fabricar nanopartículas magnéticas aglomerantes recubiertas con alcoxisilano
US20130178691A1 (en) * 2012-01-11 2013-07-11 Petr Saha Electrically lossy magnetic liquid composition for controlled tissue heating
US20130195752A1 (en) 2012-02-01 2013-08-01 Regents Of The University Of Minnesota Functionalized nanoparticles and methods of use thereof
KR102263685B1 (ko) 2012-03-21 2021-06-11 다케다 야쿠힌 고교 가부시키가이샤 Tfpi 저해제 및 사용 방법
JP6378170B2 (ja) 2012-04-12 2018-08-22 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 異なる医薬品の制御送達のためのビヒクル
CA2872652A1 (en) * 2012-05-07 2013-11-14 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
TWI583395B (zh) * 2012-05-22 2017-05-21 長庚大學 A mixture of cells for promoting cell uptake and a preparation method thereof
DE102012213839B4 (de) * 2012-08-03 2017-06-14 Leibniz-Institut Für Festkörper- Und Werkstoffforschung Dresden E.V. Verfahren zur kontrollierten Bewegung von Objekten in flüssigen Medien
JO3685B1 (ar) 2012-10-01 2020-08-27 Teikoku Pharma Usa Inc صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها
US20150272922A1 (en) * 2012-11-09 2015-10-01 Bioniche Life Sciences Inc. Compounds for Reducing Glucocorticoids, and Methods of Treatment Thereof
CN103239430B (zh) * 2013-05-08 2015-01-07 首都医科大学 拉帕醇在制备预防和/或治疗恶性胶质瘤的产品中的应用
RU2554219C2 (ru) * 2013-05-17 2015-06-27 Общество с ограниченной ответственностью "ТехноМикрон" Способ лазерной термотерапии кожи и ее придатков, фармацевтическая композиция для него и их применение
JP6387400B2 (ja) 2013-05-30 2018-09-05 ナノビオティックスＮａｎｏｂｉｏｔｉｘ 医薬組成物、その製造および使用
CN103820492A (zh) * 2013-10-29 2014-05-28 王深明 功能化纳米儿茶素的基因导入材料及其制备方法
KR102460800B1 (ko) 2013-11-01 2022-10-31 예일 유니버시티 면역요법용 모듈러 입자
RU2548722C1 (ru) * 2013-12-06 2015-04-20 Федеральное государственное бюджетное учреждение "Национальный исследовательский центр "Курчатовский институт" Противоопухолевое лекарственное средство пролонгированного действия на основе противоопухолевого препарата, ингибитора синтеза эстрогенов - анастрозола
US9381171B2 (en) 2013-12-19 2016-07-05 Samsung Electronics Co., Ltd. Composition including dapsone for preventing or treating side effect of steroid in subject and use of the composition
US9320749B2 (en) 2014-01-06 2016-04-26 University Of Wyoming Nanoparticle delivery system for targeted anti-obesity treatment
CN103877029B (zh) * 2014-03-10 2015-10-21 同济大学 一种磁性载5-氟尿嘧啶聚乳酸羟基乙酸共聚物材料的制备方法
EP2921179A1 (en) * 2014-03-17 2015-09-23 Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) Micellar nanoparticles containing antitumoral glycosides
WO2015148971A2 (en) * 2014-03-27 2015-10-01 Research Foundation Of The City University Of New York Method for detecting or treating triple negative breast cancer
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
PT3223796T (pt) 2014-11-25 2021-09-28 Curadigm Sas Composições farmacêuticas, preparação e suas utilizações
HUE062561T2 (hu) * 2014-11-25 2023-11-28 Curadigm Sas Legalább két eltérõ nanorészecskéket és egy gyógyászati vegyületet kombináló gyógyászati készítmény, annak elõállítása és alkalmazásai
NZ769187A (en) 2014-11-25 2023-07-28 Curadigm Sas Pharmaceutical composition, preparation and uses thereof
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
US9795624B2 (en) 2015-05-04 2017-10-24 Research Foundation Of The City University Of New York Cationic polymers as co-drugs for chemotherapeutic agents
WO2016189125A1 (en) 2015-05-28 2016-12-01 Nanobiotix Nanoparticles for use as a therapeutic vaccine
CN107007595B (zh) * 2015-12-01 2019-01-25 哈尔滨商业大学 水鬼蕉新碱a在制备抗炎药物中的应用
CN106074562B (zh) * 2016-06-16 2018-10-09 武汉大学 桦木酸作为机体镉清除剂的应用
US11260132B2 (en) 2017-03-16 2022-03-01 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
KR20200010343A (ko) 2017-05-19 2020-01-30 루넬라 바이오테크 인코포레이티드 안티미토신: 암 줄기 세포를 근절하기 위한 미토콘드리아 생물발생의 표적화 억제제
KR101970808B1 (ko) * 2017-07-21 2019-04-22 스노우화이트팩토리(주) 화합물이 직접 결합된 마그헤마이트 나노입자 및 이의 제조방법
KR102004333B1 (ko) * 2017-12-13 2019-07-26 단국대학교 천안캠퍼스 산학협력단 내부에 공동을 가지는 구형 나노입자 및 그 용도
PL424773A1 (pl) * 2018-03-06 2019-09-09 Nanovelos Spółka Akcyjna Enkapsulowana polisacharydem antracyklina do zastosowania w leczeniu nowotworów
RU2665922C1 (ru) * 2018-04-24 2018-09-05 Федеральное государственное бюджетное учреждение науки "Федеральный исследовательский центр "Казанский научный центр Российской академии наук" Фосфониевые соли на основе бетулиновой кислоты, обладающие цитотоксической активностью в отношении аденокарциномы предстательной железы
SG11202010430QA (en) * 2018-04-24 2020-11-27 Amgen Inc Method for making injectable pharmaceutical compositions
JP7402827B2 (ja) * 2018-06-11 2023-12-21 エピセントアールエックス，インコーポレイテッド 医薬注入デバイス、系および方法
US11464858B2 (en) 2018-06-23 2022-10-11 University Of Wyoming Magnetic nanoparticle delivery system for pain therapy
WO2020194034A1 (en) 2019-03-27 2020-10-01 Universidad De Chile Nanoparticle of chitosan and cyclodextrin containing encapsulated interferon and pharmaceutical compositions that contain it
CN110024721B (zh) * 2019-04-29 2021-09-21 中国水产科学研究院北戴河中心实验站 一种诱导鲆鲽鱼类卵巢生殖细胞凋亡的方法
CN110201216B (zh) * 2019-07-24 2021-10-08 中国人民解放军陆军军医大学第二附属医院 一种用于贯穿伤快速止血材料及其制备方法
CA3160054A1 (en) 2019-12-11 2021-06-17 Bryan ORONSKY Medication infusion devices, systems, and methods
MX2019015508A (es) 2019-12-18 2021-06-21 Univ Guadalajara Nanopartículas para el tratamiento del cáncer.
CN110935018A (zh) * 2019-12-23 2020-03-31 新乡医学院 治疗乳腺癌的药物或组合物
CN111494382A (zh) * 2020-05-28 2020-08-07 吉林大学 氯化两面针碱的新应用
CN112410295B (zh) * 2020-11-20 2023-07-28 华东理工大学 一种控制细胞间相互作用的细胞表面工程方法及其应用
CN112274525B (zh) * 2020-12-04 2022-04-08 遵义医科大学 一种化疗药物组合物及其应用
CN113274396A (zh) * 2021-06-09 2021-08-20 重庆医科大学 植物固醇在制备预防或治疗肺癌药物中的应用
CN113711960A (zh) * 2021-09-30 2021-11-30 北部湾大学 一种降低海水珍珠贝异种移植免疫排斥的方法
CN116763756A (zh) * 2022-10-11 2023-09-19 中国科学院化学研究所 一种脂质纳米颗粒及其制备方法和应用
CN116271028A (zh) * 2023-03-14 2023-06-23 浙江省人民医院 一种免疫调节性斑蝥素磁响应纳米药物及制备方法
CN116143705B (zh) * 2023-04-11 2023-06-30 齐泽(云南)生物科技有限公司 一种药用化合物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554638A (en) * 1993-05-24 1996-09-10 Duke University Methods for improving therapeutic effectiveness of agents for the treatment of solid tumors and other disorders
US5411730A (en) * 1993-07-20 1995-05-02 Research Corporation Technologies, Inc. Magnetic microparticles
DE19515820A1 (de) 1995-04-29 1996-10-31 Inst Neue Mat Gemein Gmbh Verfahren zur Herstellung schwach agglomerierter nanoskaliger Teilchen
US6147205A (en) * 1995-12-15 2000-11-14 Affymetrix, Inc. Photocleavable protecting groups and methods for their use
DE19614136A1 (de) * 1996-04-10 1997-10-16 Inst Neue Mat Gemein Gmbh Verfahren zur Herstellung agglomeratfreier nanoskaliger Eisenoxidteilchen mit hydrolysebeständigem Überzug
DE19714949A1 (de) 1997-04-10 1998-10-15 Inst Neue Mat Gemein Gmbh Verfahren zum Versehen einer metallischen Oberfläche mit einer glasartigen Schicht
DE19726282A1 (de) * 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
WO2000006244A2 (en) * 1998-07-30 2000-02-10 Hainfeld James F Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
DE19912798C1 (de) * 1999-03-10 2000-02-17 Andreas Jordan Verfahren zur Kultivierung von Krebszellen aus Humangewebe und Vorrichtung zur Aufbereitung von Gewebeproben
DE19912502A1 (de) * 1999-03-19 2000-09-21 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen, Komplexe mit Polynukleotiden und deren Verwendung
DE19940220B4 (de) * 1999-08-19 2007-05-03 Magforce Nanotechnologies Ag Medizinisches Präparat zur Behandlung von Arthrose, Arthritis und anderen rheumatischen Gelenkerkrankungen
US6530944B2 (en) * 2000-02-08 2003-03-11 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
DE10020376A1 (de) * 2000-04-26 2001-11-08 Inst Zelltechnologie E V Dynamische Marker
DE10059151C2 (de) 2000-11-29 2003-10-16 Christoph Alexiou Magnetische Partikel zur zielgerichteten regionalen Therapie und Verwendung derselben
CN1646549A (zh) * 2002-02-04 2005-07-27 财团法人理工学振兴会 结合铁氧体的有机物及其制备方法
JP2004305055A (ja) 2003-04-04 2004-11-04 Hitachi Maxell Ltd 磁性複合粒子およびその製造方法
WO2005044224A2 (en) * 2003-05-02 2005-05-19 Case Western Reserve University Drug delivery system based on polymer nanoshells
US20050090732A1 (en) * 2003-10-28 2005-04-28 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles
PT1853250E (pt) * 2005-02-18 2012-02-03 Abraxis Bioscience Llc Combinações e modos de administração de agentes terapêuticos e terapia de combinação
DE102005016873A1 (de) * 2005-04-12 2006-10-19 Magforce Nanotechnologies Ag Nanopartikel-Wirstoff-Konjugate
DE102005039579B4 (de) 2005-08-19 2022-06-30 Magforce Ag Verfahren zur Einschleusung von therapeutischen Substanzen in Zellen

Also Published As

Publication number Publication date
EP2266544A2 (de) 2010-12-29
US20160067338A1 (en) 2016-03-10
CN101299998A (zh) 2008-11-05
DE102005039579B4 (de) 2022-06-30
CA2619278A1 (en) 2007-02-02
US9827312B2 (en) 2017-11-28
CA2619278C (en) 2013-08-06
AU2006281783B2 (en) 2011-07-14
IL189079A0 (en) 2008-08-07
BRPI0614835A2 (pt) 2012-12-04
EP2266544A3 (de) 2012-08-08
EP2266544B1 (de) 2017-06-28
WO2007019845A2 (de) 2007-02-22
US20080187595A1 (en) 2008-08-07
AU2006281783A1 (en) 2007-02-22
US20120225128A1 (en) 2012-09-06
JP5512968B2 (ja) 2014-06-04
JP2009504688A (ja) 2009-02-05
IL189079A (en) 2015-08-31
EP1917004A2 (de) 2008-05-07
PL2266544T3 (pl) 2017-10-31
WO2007019845A8 (de) 2008-06-19
RU2008110324A (ru) 2009-09-27
DK2266544T3 (en) 2017-10-02
RU2480201C2 (ru) 2013-04-27
CN102716068A (zh) 2012-10-10
KR20080034925A (ko) 2008-04-22
WO2007019845B1 (de) 2007-06-14
KR20110094222A (ko) 2011-08-22
DE102005039579A1 (de) 2007-02-22
WO2007019845A3 (de) 2007-04-19
ES2635493T3 (es) 2017-10-04

Similar Documents

Publication Publication Date Title
PT2266544T (pt) Método para introdução de substâncias terapêuticas em células
GB0526291D0 (en) Therapeutic method
GB2411178A8 (en) Apparatus for culturing cells
LT2573166T (lt) T ląstelių paruošimo būdas ląstelių terapijai
EP1897008A4 (en) PROCESS FOR CREATING STANDARD CELLS DESIGNED ON THE BASIS OF PRIMITIVES
EP1813677A4 (en) PROCESS FOR MAKING BASIC SUBSTANCE
IL184262A (en) A method for culturing cells in culture
EP2022843A4 (en) APPARATUS FOR SELECTING CELLS
EP2169070A4 (en) METHOD FOR INTRODUCING A FOREIGN SUBSTANCE INTO A CELL WALL CELL
IL185207A0 (en) Method and apparatus for separating cells
GB0522303D0 (en) Culture method
EP1906975A4 (en) METHOD FOR THE TREATMENT OF SICKLE CELL DISEASE AND CONSEQUENCES OF SICKLE CELL DISEASE
GB0904267D0 (en) Method for cell analysis
EP1753867A4 (en) FERMENTATION PROCESSES
EP1721871A4 (en) PROCESS FOR GENERATING BIOGAS
ZA200606178B (en) Water-softening method
EP1776182A4 (en) APPARATUS FOR ENCAPSULATING CELLS
EP1725652A4 (en) CULTURE PROCESSES OF CRYPTOSPORIDIUM
HU0501174D0 (en) Apparatus for introducing organwind
GB0513631D0 (en) Electrode and method for making electrode
GB0607153D0 (en) Therapeutic Method
GB0413136D0 (en) Water-softening method
TWI315261B (en) Method for transferring-printing
EP1871871A4 (en) PROCESS FOR ACTIVATION OF T4 LYMPHOCYTES
IL184372A0 (en) Method for delivering interferon-??